EUVIMEDEUVIMED entdecken
Editorial

Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?

Davide Rossi iD

Journal of Clinical Oncology · 2025-12 · 43 (34) · 3631-3635

DOI: 10.1200/jco-25-01932 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von Davide Rossi. Beteiligte Einrichtung: Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

ORCID-Profile: Davide Rossi

Zitieren

APA

Rossi, D. (2025). Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?. Journal of Clinical Oncology, 43(34), 3631-3635. https://doi.org/10.1200/jco-25-01932

Vancouver

Rossi D. Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?. Journal of Clinical Oncology. 2025;43(34):3631-3635. doi:10.1200/jco-25-01932

BibTeX
@article{Rossi2025,
  author = {Rossi, Davide},
  title = {Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {34},
  pages = {3631--3635},
  doi = {10.1200/jco-25-01932}
}
Kostenlos starten →